Analyst
Baird
Equibles does not estimate personal net worth.
Robbie Bamberger is recorded as Analyst at Baird. Robbie Bamberger has spoken on 1 earnings call and 5 other investor events across 6 companies, most recently for Natera, Inc. on September 15, 2026. Those appearances were for Natera, Inc. (NTRA), Twist Bioscience Corp (TWST), Castle Biosciences Inc (CSTL), Revvity, Inc. (RVTY), Qiagen N.V. (QGEN) and 1 other company. The companies whose calls Robbie Bamberger spoke on are classified in the Healthcare and Technology sectors.
“I'm pleased to have Mike Brophy, CFO, here with us. Yeah, I guess before we get into specific segments, it would be great for you to just, giving a quick snapshot of the company, coming off a Q2 print, what went right in Q2, anything you'd point out to investors about this quarter?”
“I'm a senior research analyst here at Baird covering life sciences and diagnostics. Pleased to be joined by Emily LaProust, who's the co-founder and CEO of TWIST, along with Adam Loponis, who's TWIST CFO.”
“Very pleased to have Derek Matzhold, Castle's founder, president, CEO, and Frank Stokes, CFO.”
“I'm very pleased to be joined this morning by Steve Willoughby, senior VP of investor relations at Revity. Steve, thanks for making the trip.”
“We're pleased to welcome Kyogen this afternoon. Especially pleased to welcome John Pratt, who became Kyogen's CEO on September 1st. So we're catching him right at the two-week mark.”
Baird
Analyst
Transcript header (unverified)
NTRA
Diagnostics & Research · Healthcare
QGEN
Diagnostics & Research · Healthcare
RVTY
Diagnostics & Research · Healthcare
Information Technology Services · Technology
